TWA
ENTA icon

TCI Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

TCI Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-154
Closed -$6.23K – 824
2023
Q1 		$6.23K Buy
+154
New +$7.35K ﹤0.01% 1376
2022
Q2 		– Sell
-70
Closed -$5K – 2335
2022
Q1 		$5K Hold
70
– – ﹤0.01% 1523
2021
Q4 		$5K Hold
70
– – ﹤0.01% 1640
2021
Q3 		$4K Buy
70
+29
+71% +$1.43K ﹤0.01% 1725
2021
Q2 		$2K Buy
+41
New +$2.01K ﹤0.01% 1989
2016
Q2 		– Sell
-40
Closed -$1K – 1314
2016
Q1 		$1K Buy
+40
New +$1.11K ﹤0.01% 1069

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCI Wealth Advisors's ENTA Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2023, closing a stake of 154 shares — an estimated $6.23K sold.

TCI Wealth Advisors first reported a position in ENTA in Q1 2016 and held it in 6 quarters. The position peaked at $6.23K in Q1 2023. 133 funds tracked by Wall St. Rank hold ENTA as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 154 Enanta Pharmaceuticals shares in Q2 2023, an estimated $6.23K.
  • TCI Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • TCI Wealth Advisors's Enanta Pharmaceuticals position peaked at $6.23K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.